Key facts
- It has raised $3.0M; the latest was Early Stage VC ($1.4M) in Jul 2025.
- Notable investors include Lotus Lake Ventures, Fosun Health Capital, Xiangtang Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Southern Element
- ·The full record, as it builds
Funding rounds
No funding rounds for Southern Element are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Southern Element
Provider of functional hemostatic polysaccharides and medical aesthetic polysaccharides, intended to provide quality products and services to various industries. The company focuses on hemostatic material and new dermal fillers applications, enabling patients with new treatment of first aid for bleeding and dermal fillers.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- nfybio.com/
- Ownership
- Privately Held (backing)
Southern Element doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Southern Element shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Southern Element in its N-PORT filings yet. We sweep new filings monthly.